Metaplanet
3350
Nippon Telegraph & Telephone
9432
Generation Pass
3195
4
Pacific Metals
5541
5
Remixpoint
3825
JP Stock MarketDetailed Quotes
4559 Zeria Pharmaceutical
- 2148
- +37+1.75%
20min DelayTrading Mar 3 09:13 JST
114.10BMarket Cap12.25P/E (Static)
2151High2129Low19.20KVolume2129Open2111Pre Close41.00MTurnover250552wk High0.08%Turnover Ratio53.12MShares192152wk Low170.93EPS TTM54.41BFloat Cap3170Historical High12.25P/E (Static)25.33MShs Float705Historical Low175.39EPS LYR1.04%Amplitude45.00Dividend TTM1.11P/B100Lot Size2.09%Div YieldTTM
Zeria Pharmaceutical News
Zeria Pharmaceutical: [Delayed]Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31,2025[Under Japanese GAAP]
Zeria Pharmaceutical: Summary of Financial Results for the third quarter 2025
Zeria Pharmaceutical: Legal Advance Disclosure Documents (Merger) (Kenso Pharmaceutical Co., Ltd.)
Zeria Pharmaceutical: Notice regarding changes (expansion) of shareholder benefits
Zeria Pharmaceutical: Notice of conclusion of a marketing and distribution agreement between Tillotts Pharma and Pioneer Pharma in the People's Republic of China
Zeria Pharmaceutical: [Delayed]Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2025[Under Japanese GAAP]
Zeria Pharmaceutical: Summary of Financial Results for the second quarter 2025
Zeria Pharmaceutical: Notice regarding changes in responsibilities of executive officers
Zeria Pharmaceutical: Announcement of the new release of “Heparise W Shine”
Zeria Pharmaceutical: Notice of obtaining approval for manufacture and sale of the drug ZG-801 (Virtasa) for treating hyperkalemia
Zeria Pharmaceutical: [Delayed] Consolidated financial results for the first three months of the fiscal year ending on March 31, 2025 [based on Japanese accounting standards].
Zeria Pharmaceutical: Overview of Q1 2025 earnings report.
Zeria Pharmaceutical: Announcements of individual stocks: Development and sales contract for functional dyspepsia treatment using acotiamide hydrochloride hydrate in European, USA, and Canada regions.
Zeria Pharmaceutical: Announcements of individual stocks regarding the absorption merger (simple merger, abbreviated merger) of a wholly-owned subsidiary.
Zeria Pharmaceutical: Announcements of individual stocks regarding compliance with listing maintenance criteria.
Zeria Pharmaceutical: [Delayed] Consolidated Earnings for the Fiscal Year Ended 2024/3/31 [Japanese Accounting Standards]
Zeria Pharmaceutical: 2024 financial results overview
Zeria Pharmaceutical: Notice regarding executive personnel affairs
Zeria Pharmaceutical: Notice Concerning Organizational Changes and Executive Personnel
Zeria Pharmaceutical: [Delayed]Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2024[Japanese GAAP]